Boca Raton, Florida, April 22, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above market warrant exercise price  that include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzhzimer’s Disease program (as further described  below).  The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering.

佛罗里达州博卡拉顿，2024年4月22日（环球通讯社）--INmune Bio，Inc.（纳斯达克：INMB）（以下简称“公司”）是一家临床阶段免疫学公司，专注于开发利用患者先天免疫系统对抗疾病的治疗方法，今天宣布，该公司已签订最终协议，以高于市场的权证行使价格出售和购买571592股普通股，其中包括根据该公司第二阶段阿尔茨齐默氏病计划（如下所述）的积极顶线数据加速条款。认股权证赋予投资者在登记的直接发售中购买571592股普通股额外股份的权利。

The offering was priced at the market based on the Friday, April 19th Nasdaq consolidated closing bid price of $8.32 per share. The exercise price of the warrants is $9.152, which represents a 10% premium to the price at which the common shares were offered. The warrants terminate on the earlier of (1) the two (2) year anniversary of the initial exercise date of the warrant or (2) thirty (30) trading days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the “Termination Date”).

此次发行是根据4月19日星期五纳斯达克综合收盘价每股8.32美元在市场上定价的。认股权证的行权价格为9.152美元，比普通股发行价格溢价10%。认股权证在（1）认股权证初始行权日期的两（2）周年纪念日或（2）XPro1595第二阶段阿尔茨海默氏病计划中的顶线数据（EMACC）报告后的三十（30）个交易日（以下简称“终止日期”）终止。

The gross proceeds of this offering are approximately $4.8 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 24, 2024, subject to the satisfaction of customary closing conditions. Members of management and the Company’s board of directors and certain key employees participated in the offering and will pay a combined offering price for the common stock and warrants of $8.445 per share and warrant, and  in the case of officers and directors that participated in the offering, if the warrant t.

在扣除配售代理费和费用之前，本次发行的总收益约为480万美元。预计本次发行将于2024年4月24日左右结束，但须符合惯例的结束条件。管理层成员、公司董事会成员和某些关键员工参与了此次发行，并将为普通股和认股权证支付每股8.445美元的合并发行价格和认股权证，如果高管和董事参与了此次发行，则认股权证的价格为每股8.445美元。

The Company intends to use the net proceeds for completing the ongoing Phase 2 trial (AD02) in patients with Early Alzheimer’s Disease (AD) using XPro™ and the metastatic castration-resistant prostate cancer (mCRPC) Phase 1 trial using the INKmune technology.

该公司打算使用净收益完成正在进行的使用XPro™的早期阿尔茨海默病（AD）患者2期试验（AD02）和使用INKmune技术的转移性去势抵抗性前列腺癌（mCRPC）1期试验。

LifeSci Capital is acting as sole placement agent for this offering.

LifeSci Capital担任本次发行的独家配售代理。

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-254221) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

本次发行是根据先前向美国证券交易委员会（“SEC”）提交的表格S-3（文件号333-254221）上的有效货架登记声明进行的。描述拟议发售条款的招股说明书补充资料将提交给美国证券交易委员会，并可在美国证券交易委员会的网站上查阅http://www.sec.gov.

Electronic copies of the prospectus supplement may be obtained, when available, from LifeSci Capital LLC 250 West 55th Street, Suite 3401, New York, New York 10019 or by telephone at (646) 876-5059 or by email at ddepalma@lifescicapital.com. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering..

可从LifeSci Capital LLC 250 West 55th Street，Suite 3401，New York 10019或致电（646）876-5059或通过电子邮件ddepalma@lifescicapital.com.在投资本次发行之前，利益相关方应完整阅读招股说明书补充资料和随附招股说明书以及公司向美国证券交易委员会提交的其他文件，这些文件通过引用纳入招股说明书补充资料和随附招股说明书中，这些文件提供了有关公司和本次发行的更多信息。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或招揽购买要约，也不构成在根据任何州或司法管辖区的证券法注册或取得资格之前，在任何州或司法管辖区出售这些证券都是非法的。

About INmune Bio, Inc.

关于免疫生物公司。

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases.

INmune Bio Inc.是一家上市（纳斯达克股票代码：INMB）的临床阶段生物技术公司，专注于开发针对先天免疫系统的治疗方法以对抗疾病。INmune Bio有两个产品平台都在临床试验中：显性负性肿瘤坏死因子（DN-TNF）产品平台利用显性负性技术选择性中和可溶性TNF，这是先天免疫功能障碍的关键驱动因素，也是许多疾病的机制驱动因素。

DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease, and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer.

DN-TNF候选产品正在进行临床试验，以确定它们是否可以治疗癌症（INB03™），早期阿尔茨海默病和难治性抑郁症（XPro™）。自然杀伤细胞引发平台包括INKmune™开发用于引发患者的NK细胞，以消除癌症患者的微小残留疾病。

INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com..

INmune Bio的产品平台利用精准医学方法治疗各种血液和实体瘤恶性肿瘤以及慢性炎症。欲了解更多信息，请访问www.inmunebio.com。

Forward Looking Statements

前瞻性声明

Clinical trials are in the early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.

临床试验处于早期阶段，无法保证会取得任何具体结果。本新闻稿中包含的任何不描述历史事实的声明可能构成《1995年私人证券诉讼改革法》中定义的前瞻性声明。本新闻稿中包含的任何不描述历史事实的声明可能构成《1995年私人证券诉讼改革法》中定义的前瞻性声明。

Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

本文中包含的任何前瞻性陈述均基于当前的预期，但存在许多风险和不确定性。由于这些风险和不确定性，某些事件和情况的实际结果和时间可能与前瞻性声明中描述的结果和时间有重大差异。

INB03™, XPro1595 (XPro™), and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved.

INB03™、XPro1595（XPro™）和INKmune™仍在进行临床试验或准备开始临床试验，尚未获得美国食品和药物管理局（FDA）或任何监管机构的批准，因此无法保证它们将获得FDA或任何监管机构的批准或取得任何具体结果。

The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

可能导致实际未来结果与当前预期存在重大差异的因素包括但不限于与公司生产更多临床试验药物的能力有关的风险和不确定性；该公司有大量额外资金继续运营，并进行研发、临床研究和未来产品商业化；以及公司的业务、研究、产品开发、监管批准、营销和分销计划和战略。